louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01757561: The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane
Official title: The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Hypoxia
Postoperative Cognitive Dysfunction
Keywords: jugular bulb oxygen saturation
postoperative cognitive dysfunction
propofol
sevoflurane
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2012-12-31
Enrollment: 144
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients undergoing elective major surgery

Brief summary: the purpose of this study is to investigate whether propofol and sevoflurane have difference effect on cerebral oxygenation .

Detailed description: the purpose of this study:(1) to investigate the incidence of preoperative cerebral oxygenation abnormity (SjvO2 \<55%) and its relationship with intraoperative cerebral desaturation and POCD. (2) To investigate the change of intraoperative cerebral oxygen supply and demand balance and the incidence of cerebral desaturation in patients with abnormal preoperative cerebral oxygenation during sevoflurane anesthesia. (3)To investigate the incidence of early POCD in patients with abnormal preoperative cerebral oxygenation during sevoflurane and propofol anesthesia.

Eligibility criteria: Inclusion Criteria:

* scheduled to take major surgery under general anesthesia over 18 years old classified as ASA class three or less

Exclusion Criteria:

* have a diagnosis of cerebrovascular disorder

Primary outcomes:
measure: the Incidence of Intraoperative Desaturation Between Propofol and Sevoflurane General Anesthesia
timeFrame: baseline ,every hour in the operation period,after extubation
Secondary outcomes:
measure: the Incidence of Postoperative Cognitive Disfunction(POCD)Between Propofol and Sevoflurane General Anesthesia
timeFrame: 1-3days、5-7days after operation
measure: the Change in the Level of Serum BDNF(Brain-derived Neurotrophic Factor ) Between Propofol and Sevoflurane Anesthesia
timeFrame: before anesthesia, after extubation ,1day after operation
measure: the Change in the Level of Serum s-100β Between Propofol and Sevoflurane Anesthesia
timeFrame: before anesthesia,after extubation,1 day after operation
Other outcomes:
measure: Vital Signs
timeFrame: baseline , evey hour in the operation,afte extubation
measure: Blood Gas Analysis
timeFrame: baseline,every hour in the operation,after extubation
Locations:
city: Guang Zhou
country: China
facility: the First Affiliated Hospital of Sun YetSen University
state: Guangdong
Study officials:
affiliation: the First Affiliated Hospital of SunYetSen University
name: Guo J Ying, Master
role: STUDY_CHAIR
References:
Clinical trial NCT03301961: Multiplex Analysis of Circulating Tumor DNA
Official title: The Clinical Applications of Multiplex Analysis of Circulating Tumor DNA Biomarkers in Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Carcinoma
Non-small-cell Lung Cancer
Lung Neoplasm
Keywords: Circulating Tumor DNA
Early diagnosis
Surveillance
Methylation
Somatic mutation
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2017-10-04
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patient are found nodules in pulmonary and prepare for surgery

Brief summary: Lung cancer is the leading cause of cancer-related death in China. This study will explore the applications of multiplex analysis of circulating tumor DNA biomarkers for diagnosis and surveillance of lung cancer patients

Detailed description: Non-small cell lung cancer (NSCLC) constitutes about 85% of all newly diagnosed cases of lung cancer and continues to be the leading cause of cancer-related deaths worldwide.Early diagnosis and monitoring tumor recurrence after surgery are still far from satisfying.

Circulating tumor DNA(ctDNA) detection has been proved to be feasible in early stage NSCLC in previous studies.Both genomic mutation and methylation a promising biomarker.Therefore,this study will perform multiplex detection of ctDNA,analysing mutations, methylation and other biomarkers,focusing on the early diagnosis and postoperative surveillance for NSCLC patients.

Eligibility criteria: Inclusion Criteria:

1. Sign informed consent and consent to participate in this study;
2. Found small nodules in pulmonary by CT and prepare for surgery;

Exclusion Criteria:

1. Malignant tumor history within the past 5 years;
2. Receiving chemotherapy, radiotherapy or targeted therapy before surgery;
3. No matching tissue or blood samplesUnqualified blood samples
4. Lesion is pure ground glass opacity.

Primary outcomes:
measure: The sensitivity and specificity of multiplex peripheral blood ctDNA biomarkers in the diagnosis of non-small cell lung cancer
timeFrame: 12 months
Secondary outcomes:
measure: Comparing the sensitivity and specificity of each peripheral blood biomarkers for the diagnosis of non-small cell lung cancer
timeFrame: 12 months
measure: The sensitivity and specificity of multiplex peripheral blood ctDNA biomarkers for tumor relapse detection
timeFrame: 36 months
measure: Lead time of tumor relapse detection by multiplex ctDNA biomarkers than radiographic approaches
timeFrame: 36 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People's Hospital
state: Beijing
Study officials:
affiliation: Peking University People's Hospital
name: Kezhong Chen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01574261: Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Polycystic Ovary Syndrome
Keywords: Polycystic Ovary Syndrome
Cardiovascular risk
Metabolic Syndrome
Lead sponsor: Catholic University of the Sacred Heart
Sponsor class: OTHER
First posted: 2012-04-10
Enrollment: 70
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Polycystic ovary syndrome (PCOS) is associated with an increased cardiovascular risk. The aim of the study was to evaluate long-term effects of inositol on some cardiovascular risk factors in PCOS patients.


Eligibility criteria: Inclusion Criteria:

* Polycystic Ovary Syndrome
* Age \>18 and \<35

Exclusion Criteria:

* Chronic or acute inflammatory disease, cancer, autoimmune disease, treatment during the last 6 months prior to our evaluation, DM2, hypertension, major surgery in the last 3 months or other hormonal dysfunctions (hypothalamic, pituitary, thyroidal, or adrenal causes).

Primary outcomes:
measure: CD4+ CD28 null T-lymphocyte frequency
timeFrame: five minutes
Secondary outcomes:
measure: insulinaemic area OGTT AUCi, lipid profile, androgen levels
timeFrame: 120 minutes
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Università cattolica S. Cuore
Study officials:
References:
citation: Niccoli G, Apa R, Lanzone A, Liuzzo G, Spaziani C, Sagnella F, Cosentino N, Moro F, Martinez D, Morciano A, Baca M, Pazzano V, Gangale MF, Tropea A, Crea F. CD4+CD28 null T lymphocytes are expanded in young women with polycystic ovary syndrome. Fertil Steril. 2011 Jun 30;95(8):2651-4. doi: 10.1016/j.fertnstert.2011.01.129. Epub 2011 Feb 16.
Clinical trial NCT00674661: Corneal Collagen Cross-Linking for Ectasia (CXL)
Official title: Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Ectasia
Keywords: ectasia
cross-linking
crosslinking
cornea
riboflavin
UVA
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2008-05-08
Enrollment: 130
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.

Detailed description: Subjects are randomized to a control group or a treatment group, with the control group crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is performed as a single treatment. Subjects are followed for 12 months after the procedure to evaluate the long term effects of corneal collagen cross-linking.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of ectasia after refractive surgery
* Documented ectasia on Pentacam or topography map
* BSCVA worse than 20/20
* Must complete all study visits

Exclusion Criteria:

* History of delayed wound healing
* History of corneal melt or corneal dystrophy

Primary outcomes:
measure: Mean Change From Baseline in Maximum Keratometry (Kmax)
timeFrame: baseline,12 months
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Shiley Eye Center
state: California
city: San Diego
country: United States
facility: Gordon -Weiss Vision Institute
state: California
city: Miami
country: United States
facility: Center for Excellence in Eye Care
state: Florida
city: Indianapolis
country: United States
facility: Price Vision Group
state: Indiana
city: Kansas City
country: United States
facility: Durrie Vision
state: Kansas
city: Baltimore
country: United States
facility: Wilmer Eye Institute at Johns Hopkins University
state: Maryland
city: Minneapolis
country: United States
facility: Minnesota Eye Consultants
state: Minnesota
city: Teaneck
country: United States
facility: Cornea & Laser Eye Institute; Hersh Vision Group
state: New Jersey
city: New York
country: United States
facility: Edward Harkness Eye Institute at Columbia University Medical Center
state: New York
city: Rockville Centre
country: United States
facility: Ophthalmic Consultants of Long Island
state: New York
Study officials:
affiliation: Cornea and Laser Eye Institute
name: Peter Hersh, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Greenstein SA, Fry KL, Hersh PS. Effect of topographic cone location on outcomes of corneal collagen cross-linking for keratoconus and corneal ectasia. J Refract Surg. 2012 Jun;28(6):397-405. doi: 10.3928/1081597X-20120518-02.
Clinical trial NCT01341561: Relevance of Biomarkers in the Process of Weaning
Official title: The Relevance of Biochemical Markers in the Process of Weaning
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Duration of Weaning
Lead sponsor: Heidelberg University
Sponsor class: OTHER
First posted: 2011-04-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: consecutively all patients on our intensive care unit who are artificially ventilated

Brief summary: The purpose of the study is to examine the relevance of biochemical markers (specific pulmonary and cardiac markers and markers of endogenous stress) in the process of weaning in patients with artificial ventilation.

Detailed description: Artificially ventilated patients on our intensive care unit will be monitored if specific biomarkers have a relevance in risk stratification, optimizing therapy, outcome and success in the process of weaning. Therefore, consecutively, specific blood parameters will be taken at time of intubation,day 1 of weaning and extubation.

Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Able and willing to understand the protocol
* At least 18 years or older

Exclusion Criteria:

* Not fulfilling inclusion criteria

Primary outcomes:
measure: success of weaning
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 30days
Secondary outcomes:
measure: follow up
timeFrame: 12 months
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Intensive Care Unit, University of Heidelberg
state: Baden-Württemberg
Study officials:
References:
Clinical trial NCT02685761: Skin Incisions and Wound Complication Rates for C-sections in Obese Women
Official title: Randomized Controlled Trial of Wound Complication Rates Between Low Transverse, Midline Vertical, and High Transverse Skin Incisions in Women With a BMI of 40 or Above Undergoing a Cesarean Section for Delivery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Obesity
Infection; Cesarean Section
Surgical Wound
Lead sponsor: Albany Medical College
Sponsor class: OTHER
First posted: 2016-02-19
Enrollment: 309
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: It is the purpose of this study to evaluate the relationship between a low transverse, vertical midline, and supra-panicular high transverse skin incisions and the rate of wound complications in women with a BMI of 40 or greater undergoing a cesarean section for delivery. So far, the choice of incision for the morbidly obese is based only on case reports. No randomized controlled trials have been done up to date comparing these methods. It is our hope that a high transverse incision will have all of the benefits of a low transverse skin incision, with the added benefit of better exposure offered by a vertical midline incision, without the added increased risk of subjecting the woman to a vertical hysterotomy.


Eligibility criteria: Inclusion Criteria:

* pre-pregnancy BMI equal or greater than 40

Exclusion Criteria:

* prior cesarean section or laparotomy

Primary outcomes:
measure: Wound Complications
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Albany
country: United States
facility: Albany Medical Center Obstetrics and Gynecology
state: New York
city: Albany
country: United States
facility: Albany Medical Center Obstetrics and Gynecology
state: New York
city: Albany
country: United States
facility: Albany Medical Center
state: New York
city: Ballston Spa
country: United States
facility: Albany Medical Center Obstetrics and Gynecology
state: New York
city: Clifton Park
country: United States
facility: Albany Medical Center Obstetrics and Gynecology
state: New York
city: Delmar
country: United States
facility: Albany Medical Center Obstetrics and Gynecology
state: New York
city: Latham
country: United States
facility: Albany Medical Center Obstetrics and Gynecology
state: New York
Study officials:
References:
Clinical trial NCT02429661: Girls First - India (2013-2015)
Official title: Girls First - India Evaluation (2013-2015)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Emotional Wellbeing
Social Wellbeing
Physical Wellbeing
Lead sponsor: CorStone
Sponsor class: OTHER
Collaborators: name: David & Lucile Packard Foundation
name: Gramin Evam Nagar Vikas Parishad (GENVP)
name: Integrated Development Foundation Nepal
First posted: 2015-04-29
Enrollment: 4592
Sex: ALL
Minimum age (years): 9
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to determine the social, emotional, physical, and educational effects of Girls First, a combined resilience and adolescent health program, vs. its components and a control group, among adolescents in India.


Eligibility criteria: Inclusion Criteria:

* Enrolled at schools or present at sites selected for study
* Must complete consent/assent process

Exclusion Criteria:

* None

Primary outcomes:
measure: Psychosocial assets and wellbeing
timeFrame: Change from baseline, measured at program completion (average of 6 months)
measure: Physical health and wellbeing
timeFrame: Change from baseline, measured at program completion (average of 6 months)
Secondary outcomes:
measure: Educational wellbeing
timeFrame: Change from baseline, measured at program completion (average of 6 months)
Other outcomes:
Locations:
city: Mill Valley
country: United States
facility: CorStone
state: California
Study officials:
affiliation: QURE Healthcare
name: John Peabody, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Leventhal KS, DeMaria LM, Gillham J, Andrew G, Peabody JW, Leventhal S. Fostering emotional, social, physical and educational wellbeing in rural India: the methods of a multi-arm randomized controlled trial of Girls First. Trials. 2015 Oct 26;16:481. doi: 10.1186/s13063-015-1008-3.
Clinical trial NCT03023761: Management of Post Endodontic Re-treatment Pain With Low-Level Laser Therapy
Official title: Management of Post Endodontic Re-treatment Pain With Low-Level Laser Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain
Keywords: Endodontic retreatments
Low level laser
Pain
Lead sponsor: Shahid Beheshti University
Sponsor class: OTHER
First posted: 2017-01-18
Enrollment: 61
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: In this clinical trial investigators aimed to evaluate Post endodontic re-treatment pain after irradiation of low level laser therapy

Detailed description: In this clinical trial, 61 patients requiring endodontic retreatments in the posterior teeth were selected. A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group. In the control group patients received placebo laser to eliminate the probable psychological effects of laser. Laser irradiation was done with a single dose of 808 nm wavelength (Whitening Lase II- Laser DMC, Samsung, Korea) with 100 mw power, and dose of 70 J/cm2 for 80 seconds. Pain severity was recorded before the treatment, immediately after the treatment and 4, 8, 12, 24 and 48 hours after the treatment by visual analogue scale (VAS). The pain scores were statistically analyzed by chi-square test between two groups. The effects of different variables on the post-operative pain experience were also studied by means of Logistic regression.

Eligibility criteria: Inclusion Criteria:

- patients requiring endodontic retreatments in the posterior teeth

Exclusion Criteria:

* systemic diseases psychologic disorders

Primary outcomes:
measure: reduction of pain after low level laser irradiation
timeFrame: baseline and 4, 8, 12, 24 and 48 hours after the treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Shahid Beheshti University
Study officials:
affiliation: Shahid Beheshti University of Medical Sciences
name: mohammad asnaashari
role: STUDY_CHAIR
References:
Clinical trial NCT06338761: Switching to E-cigarette After PCI
Official title: Prognostic Impact of Switching to E-Cigarette Use in Smokers With Coronary Artery Disease Following Percutaneous Coronary Intervention: A Nationwide Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Percutaneous coronary intervention
E-cigarette
Smoking
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2024-04-01
Enrollment: 17973
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with coronary artery disease who underwent health screening 3 years before and after the PCI

Brief summary: Despite the increasing popularity of electronic cigarettes (E-cigarettes), the prognostic impact of switching to E-cigarettes in smokers with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) remains uncertain.

Detailed description: Recently, several studies have reported that, although lower than combustible cigarette users, E-cigarette users had a significantly higher risk of future myocardial infarction (MI) or cardiovascular disease compared with non-smokers or quitters. However, because all previous studies has focused on the general healthy population, these results cannot be extrapolated for patients who already proven atherosclerotic cardiovascular disease (ASCVD), such as undergoing percutaneous coronary intervention (PCI) for coronary artery disease (CAD). Although Busch et al. previously reported that a significant minority of patients are using E-cigarettes post-acute coronary syndrome smokers, a paucity of data exists regarding the impact of such transitions on clinical outcomes in current smoker patients with CAD who have undergone PCI. In light of these considerations, the current study sought to address this gap in knowledge by evaluating the prognostic implications of smoking habit changes, including E-cigarette use, among CAD patients with current smoking status following PCI.

Eligibility criteria: Inclusion Criteria:

* patients who underwent health screening 3 years before and after the PCI

Exclusion Criteria:

* history of cancer
* history of ischemic stroke
* died within the first 3 months of follow-up from the index date
* Newly developed acute MI or received additional PCI or CABG from the index PCI date to the study index date

Primary outcomes:
measure: MACE
timeFrame: 5 years after PCI
Secondary outcomes:
measure: Cardiovascular death
timeFrame: 5 years after PCI
measure: All-cause death
timeFrame: 5 years after PCI
measure: Spontaneous myocardial infarction
timeFrame: 5 years after PCI
measure: Repeat revascularization
timeFrame: 5 years after PCI
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Ki Hong Choi, MD
role: PRINCIPAL_INVESTIGATOR
References: